The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities
Andrew L. Frelinger(University of Nottingham), Alan D. Michelson(Harvard University), Marsha L. Fox(Pediatrics and Genetics), Inge Tarnow(University of Copenhagen), Matthew D. Linden(University of Massachusetts Chan Medical School), Kenneth J. Winters(Eli Lilly (United States)), M.I. Furman(University of Massachusetts Chan Medical School), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Y. LI(University of Massachusetts Chan Medical School), M.R. BARNARD(Harvard University), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom))
Cited by 6
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617